Trial Information

Summary: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis

Status: Completed

Protocol Number: ML18349

Sponsor: Produtos Roche Químicos e Farmacêuticos S.A.

Company Division: Pharmaceutical

Official Scientific Title: An open-label, randomized study of Tacrolimus ointment on clinical response in children with atopic dermatitis

Brief Summary: This study will evaluate the efficacy and safety of Tacrolimus ointment in children with atopic dermatitis. The anticipated time on study treatment is <3 months and the target sample size is 100-500 individuals. Target sample size is 170.

Study Phase: III

Study Design / Study Details:

• Purpose: Treatment
• Allocation: Non-Randomized
• Masking: Open Label
• Control: Uncontrolled
• Assignment: Single Group
• Endpoints: Safety/Efficacy

Study Type:

Condition: Atopic Dermatitis

Intervention Type: Drug

Intervention Name: tacrolimus ointment[Protopic]

Primary Outcome: 1. Efficacy: Clinical response (>90% improvement in areas defined for treatment at baseline)

Key Secondary Outcomes: 1. Efficacy: Percent of body surface area affected; Eczema Area and Severity Index; patient's assessment of pruritus Safety: Adverse events

Inclusion Criteria:

Exclusion Criteria:

Gender: Males or Females

Age Limits: Min: 2 Years Max: 10 Years

Accepts Healthy Volunteers: No

Trial Registration Date: 08/29/2005

Date Last Updated: 06/17/2008

Link To Trial Results

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:42:59 PM